{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:25:25Z","timestamp":1773296725127,"version":"3.50.1"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study investigated the efficacy of 131iod- ine-labeled lipiodol (1311-lipiodol) as a palliative therapy, evaluated overall survival (OS) across Barcelona Clinic Liver Cancer (BCLC) stages, and determined the main prognostic factors influencing OS in patients with hepatocellular carcinoma (HCC). Patients, methods: We retrospectively analyzed 57 (44 men; mean age, 65.7 years; mean activity per session, 1.6 GBq; mean cumulative activity in patients with &gt;1 sessions, 3.9 GBq) HCC patients who underwent 1311-lipiodol therapy. A majority of patients exhibited Child-Pugh class B (53.6%) disease and a good Eastern Cooperative Oncology Group performance status (0-1; 72%). Multinodular disease was observed in 87.7% patients, bilobar disease in 73%, and portal vein occlusion (PVO) in 54%. Furthermore, 21.1% patients were staged as BCLC B and 59.6 % as BCLC C. All patients were followed until death. Results: The median OS was 6.4 months, which varied significantly with disease stage (median OS for BCLC A, B, C, and D was 29.4, 12.0, 4.6, and 2.7 months, respectively; p = 0.009); Child-Pugh score and class; presence of ascites, PVO, or extrahepatic disease; largest lesion size; favourable treatment response; international normalized ratio, baseline albumin and alpha-fetopro- tein levels. Patients with a Child-Pugh A liver disease had a longer OS. Conclusion: Currently, different treatment modalities for HCC include radioembolization, transarterial chemoemboliz- ation, and systemic therapy with sorafenib; however, 1311-lipiodol therapy remains a feasible alternative for patients without a favourable response to other therapies, particularly for patients with Child-Pugh A liver cirrhosis.<\/jats:p>","DOI":"10.3413\/nukmed-0610-13-07","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T08:19:25Z","timestamp":1390897165000},"page":"46-53","source":"Crossref","is-referenced-by-count":7,"title":["Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma"],"prefix":"10.3413","volume":"53","author":[{"given":"S.","family":"Ezziddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fimmers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Spengler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Palmedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Strunk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. H.","family":"Schild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Biersack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Risse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ahmadzadehfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"10.3413\/Nukmed-0610-13-07-1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.11.001"},{"key":"10.3413\/Nukmed-0610-13-07-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.05.003"},{"key":"10.3413\/Nukmed-0610-13-07-3","doi-asserted-by":"crossref","unstructured":"Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-355:","DOI":"10.1111\/j.1365-2036.2010.04370.x"},{"key":"10.3413\/Nukmed-0610-13-07-4","unstructured":"Bhattacharya S, Dusheiko GM. Treatment of unresectable hepatocellular carcinoma: targeted therapies using iodized oil. Princess Takamatsu Symp 1995; 25: 253-264:"},{"key":"10.3413\/Nukmed-0610-13-07-5","doi-asserted-by":"crossref","unstructured":"Bhattacharya S, Novell JR, Dusheiko GM, et al. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76: 2202-2210:","DOI":"10.1002\/1097-0142(19951201)76:11<2202::AID-CNCR2820761105>3.0.CO;2-8"},{"key":"10.3413\/Nukmed-0610-13-07-6","doi-asserted-by":"crossref","unstructured":"Borbath I, Lhommel R, Bittich L et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 905-910:","DOI":"10.1097\/00042737-200509000-00004"},{"key":"10.3413\/Nukmed-0610-13-07-7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.044750"},{"key":"10.3413\/Nukmed-0610-13-07-8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.11.001"},{"key":"10.3413\/Nukmed-0610-13-07-9","doi-asserted-by":"publisher","DOI":"10.1089\/108497801753131417"},{"key":"10.3413\/Nukmed-0610-13-07-10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"10.3413\/Nukmed-0610-13-07-11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25283"},{"key":"10.3413\/Nukmed-0610-13-07-12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0143-9"},{"key":"10.3413\/Nukmed-0610-13-07-13","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.212.3.r99se03665"},{"key":"10.3413\/Nukmed-0610-13-07-14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"N","year":"2012","journal-title":"J Hepatol"},{"key":"10.3413\/Nukmed-0610-13-07-15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.3413\/Nukmed-0610-13-07-16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61347-0"},{"key":"10.3413\/Nukmed-0610-13-07-17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247133"},{"key":"10.3413\/Nukmed-0610-13-07-18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2008.04480.x"},{"key":"10.3413\/Nukmed-0610-13-07-19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181571047"},{"key":"10.3413\/Nukmed-0610-13-07-20","first-page":"1313","volume":"35","author":"Leung","year":"1994","journal-title":"J Nucl Med"},{"key":"10.3413\/Nukmed-0610-13-07-21","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"10.3413\/Nukmed-0610-13-07-22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"10.3413\/Nukmed-0610-13-07-23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.060558"},{"key":"10.3413\/Nukmed-0610-13-07-24","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920115)69:2<346::AID-CNCR2820690212>3.0.CO;2-E"},{"key":"10.3413\/Nukmed-0610-13-07-25","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.202"},{"key":"10.3413\/Nukmed-0610-13-07-26","first-page":"1156","volume":"26","author":"Raoul","year":"1997","journal-title":"Hepatology"},{"key":"10.3413\/Nukmed-0610-13-07-27","first-page":"1782","volume":"35","author":"Raoul","year":"1994","journal-title":"J Nucl Med"},{"key":"10.3413\/Nukmed-0610-13-07-28","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4271"},{"key":"10.3413\/Nukmed-0610-13-07-29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.07.006"},{"key":"10.3413\/Nukmed-0610-13-07-30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2002.02348.x"},{"key":"10.3413\/Nukmed-0610-13-07-31","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2000.15.65"},{"key":"10.3413\/Nukmed-0610-13-07-32","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100542"},{"key":"10.3413\/Nukmed-0610-13-07-33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0038-1625116","volume":"45","author":"Risse","year":"2006","journal-title":"Nuklearmedizin"},{"key":"10.3413\/Nukmed-0610-13-07-34","doi-asserted-by":"crossref","unstructured":"Sabet A, Ahmadzadehfar H, Bruhman J et al. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization - Prediction by 18F-FDG PET. Nuklearmedizin 2014;","DOI":"10.3413\/Nukmed-0622-13-09"},{"key":"10.3413\/Nukmed-0610-13-07-35","doi-asserted-by":"crossref","unstructured":"Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140: 497-507, e492","DOI":"10.1053\/j.gastro.2010.10.049"},{"key":"10.3413\/Nukmed-0610-13-07-36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24451"},{"key":"10.3413\/Nukmed-0610-13-07-37","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911101)68:9<1878::AID-CNCR2820680905>3.0.CO;2-D"}],"container-title":["Nuklearmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.3413\/Nukmed-0610-13-07.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T02:57:29Z","timestamp":1688957849000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.3413\/Nukmed-0610-13-07"}},"subtitle":["A single-center study based on a long-term follow-up"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":37,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2018,1,2]]},"published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3413\/nukmed-0610-13-07","relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}